FDA Dental Panel To Assess Tricalcium Phosphate Downclassification May 22
This article was originally published in The Gray Sheet
A recommendation by FDA's Dental Products Panel to downclassify tricalcium phosphate granules for dental bone repair to Class II could pave the way for Bicon, Inc. to submit a 510(k) for its Biconoss bone graft
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.